The US Food and Drug Administration is seeking to improve how pharmaceutical companies assess whether their approved risk evaluation and mitigation strategy (REMS) for a marketed drug is achieving its intended goal of informing and educating patients and healthcare providers about the risks of the drug1…
You are here: Home /USA, USFDA /US FDA consults drug companies on best approaches to REMS assessment
